Pharma 2020: Challenging business models - Which path will you take?

Pharma 2020: Challenging business models, the fourth in the Pharma 2020 series, explains how even the largest pharmaceutical companies will have to collaborate more closely with players inside and outside the sector to be able to respond to the demands from the different stakeholder communities. To do so they will have to ‘profit together’, by joining forces with a wide range of organisations, from academic institutions, hospitals and technology providers to companies offering compliance programmes, nutritional advice, stress management, physiotherapy, exercise facilities and health screening.

The paper suggests that alternative business models with varying degrees of collaboration will emerge to provide a basis for the industry to operate more effectively as times change. It also evaluates the advantages and disadvantages of each alternative, their strengths and weaknesses and lists some key questions to make the transition to a new business successful.

Download this report and others from the the Pharma 2020 series.